Losartic Plus

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Losartic Plus

What is Losartic Plus?

Losartic Plus is a combination medication containing two active ingredients: losartan potassium and hydrochlorothiazide. It is primarily used for the management of high blood pressure, also known as hypertension.

Composition and Mechanism of Action

Each component in Losartic Plus works through a different physiological pathway to help lower blood pressure:

  • Losartan potassium: This ingredient belongs to a class of drugs known as angiotensin II receptor blockers (ARBs). It works by blocking the action of angiotensin II, a naturally occurring substance in the body that causes blood vessels to tighten and narrow. By relaxing the blood vessels, it allows blood to flow more easily.
  • Hydrochlorothiazide: This is a thiazide diuretic, often referred to as a water pill. It assists the kidneys in removing excess salt and water from the body through the urine. This process helps to reduce the total volume of fluid circulating through the blood vessels, which further contributes to lowering blood pressure.

Therapeutic Use

Losartic Plus is typically used when treatment with a single medication has not sufficiently controlled blood pressure levels. The combination of an ARB and a diuretic is intended to provide a more effective reduction in blood pressure than either medication used alone.

In addition to treating hypertension, this combination may be used in certain patients to reduce the risk of stroke, particularly those who have high blood pressure and a specific heart condition known as left ventricular hypertrophy (enlargement of the walls of the left side of the heart).

Regulatory References

  1. National Institutes of Health

What side effects are possible with Losartic Plus?

Possible Side Effects and Safety Information

The official safety information for Losartan Potassium and Hydrochlorothiazide (Losartic Plus) provides a defined set of adverse reactions and constraints based on government regulatory documentation. Adverse effects are organized by frequency and the body system affected, providing a structured view of the medicine’s risk profile.


Officially Classified Adverse Reactions

Adverse reactions classified as Common (occurring frequently in clinical trials) include dizziness, upper respiratory infection, nasal congestion, and back pain. Reactions impacting the Metabolism and Nutrition system are a key characteristic, specifically the risk of electrolyte imbalance, such as hypokalemia (low potassium) and hyperkalemia (high potassium).

Reactions affecting other organ systems include Gastrointestinal Disorders (e.g., diarrhea, abdominal pain) and Skin Disorders (e.g., photosensitivity).


Serious Safety Constraints

Official labeling includes specific, serious warnings that constrain the use of this medicine:

  • Fetal Toxicity: A Black Box Warning notes that use during the second and third trimesters of pregnancy can cause severe injury or death to the fetus, leading to a contraindication in this period.
  • Hypersensitivity: The medicine is contraindicated in patients with a known hypersensitivity to any component or to sulfonamide-derived drugs.
  • Ocular and Renal Risk: Rare but serious effects include Acute Angle-Closure Glaucoma and an increased risk of renal dysfunction, particularly in patients with pre-existing severe renal impairment or anuria.

Exposure-related risks are also documented: Symptomatic hypotension is more likely at treatment initiation, while the risk of Non-melanoma skin cancer is associated with increasing cumulative dose of the hydrochlorothiazide component.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Losartic Plus

Regulatory documents define an overdose of Losartan Potassium / Hydrochlorothiazide by the severe, extended effects of its active ingredients. Manifestations are primarily severe hypotension (low blood pressure) and tachycardia (rapid heart rate) from the Losartan component, or less commonly, bradycardia. The Hydrochlorothiazide component is associated with symptoms resulting from profound volume depletion and critical electrolyte imbalance, such as hypokalemia and hyponatremia, which may lead to neurological signs like somnolence (drowsiness).

Severe outcomes include the potential for circulatory shock secondary to hypotension, cardiac arrhythmias due to electrolyte disturbances, and, in extreme cases, stupor or coma.

Required Emergency Actions

Immediate medical attention must be sought for any suspected overdose. The official regulatory guidance states that hospital monitoring is often required, particularly for managing profound hypotension or signs of severe dehydration. Treatment is strictly defined as symptomatic and supportive, focusing on the correction of fluid volume and electrolyte abnormalities. There is no specific antidote known for this combination medicine. Hemodialysis is unlikely to remove Losartan, but Hydrochlorothiazide is dialyzable.

Therapeutic Uses of Losartic Plus

What Losartic Plus treats: main uses and benefits

Losartan Plus is generally applied across conditions characterized by periods of heightened symptoms related to elevated blood pressure. This combination medication is commonly used across conditions presenting with acute episodes of hypertension, a state where symptoms related to heightened physiological activity can create noticeable physiological strain.

The primary role of Losartan Plus is in the therapeutic domain of treating essential hypertension (high blood pressure). Furthermore, the medication is considered relevant for use in the therapeutic domain of lessening stroke risk in patients who meet specific clinical criteria, such as those diagnosed with hypertension and left ventricular hypertrophy.

The overall goal is to provide supportive relief that helps ease the overall symptom burden and allows patients to cope more steadily with symptom fluctuations. The medication is specifically used for managing the primary therapeutic areas of hypertension and stroke risk reduction in susceptible patients. The medication may contribute to improved comfort during periods of heightened symptoms.

Quick Fact: Assisting with Symptoms Related to Heightened Physiological Activity

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Losartic Plus is an anti-hypertensive combination medicine containing losartan and hydrochlorothiazide, and its use is strictly determined by official regulatory guidelines concerning patient eligibility.

Who Must Not Use This Medicine (Contraindications)

The medicine is formally contraindicated for several specific patient groups:

  • Pregnancy: It is prohibited for use during the second and third trimesters of pregnancy due to the risk of fetal harm; use must be stopped immediately upon detection of pregnancy.
  • Allergy/Hypersensitivity: Individuals with a known allergy to losartan, hydrochlorothiazide, or any other component, including sulfonamide-derived drugs (due to the hydrochlorothiazide content), must not use this medicine.
  • Kidney/Liver Function: It is contraindicated in patients with anuria (absence of urine production), severe renal impairment (creatinine clearance < 30 mL/min), or severe hepatic impairment, cholestasis, or biliary obstructive disorders.
  • Specific Co-administration: It is strictly contraindicated for coadministration with aliskiren in patients who have diabetes mellitus.

Populations with Restrictions

  • Age: Use is not recommended in children and adolescents under 18 years of age because safety and effectiveness in this pediatric population have not been established.
  • Electrolyte/Metabolic Conditions: Use is contraindicated in patients with therapy-resistant electrolyte imbalances, such as hypokalemia or hypercalcemia, and in those with symptomatic hyperuricemia (gout).

Only adult patients without any of the formal contraindications or restrictions listed above are eligible for this treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Losartan Potassium/Hydrochlorothiazide (Losartic Plus) documents specific interaction patterns that affect drug exposure, electrolyte balance, and renal function. All documented interactions establish constraints or warnings based on official labeling.

Formal Restrictions and Pharmacodynamic Effects:

  • Co-administration with Aliskiren is contraindicated in patients with diabetes, owing to the formally documented risk of increased renal impairment, hypotension, and hyperkalemia.
  • Potassium-Sparing Diuretics and Potassium Supplements are associated with an increased risk of hyperkalemia. Likewise, Salt Substitutes containing potassium fall under this restriction.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the blood pressure-lowering effect and increase the risk of renal function deterioration.
  • Lithium requires regulatory caution as its renal clearance is reduced, increasing the formal risk of toxicity. Other Antihypertensive Agents may result in an additive hypotensive effect.

Exposure Modification and Population Constraints:

  • Cholestyramine and Colestipol Resins are documented to reduce the absorption of the Hydrochlorothiazide component.
  • The enzyme inhibitor Fluconazole is documented to increase the systemic exposure of Losartan.
  • The product's use is not recommended in patients with severe renal impairment (CrCl le 30 mL/min), and Losartan exposure is significantly increased in hepatic impairment, which are population-specific constraints noted in regulatory documents.

Mechanism of Action

Angiotensin II Type 1 ( AT1) Receptor Antagonism

This component operates within the Renin-Angiotensin System ( RAS) by acting as an antagonist to the Angiotensin II Type 1 ( AT1) receptors. Losartan and its active metabolite competitively prevent the binding of Angiotensin II ( Ang II), thereby blocking the downstream hormonal cascade that facilitates vasoconstriction and triggers the adrenal glands to retain sodium and water. This mechanistic action results in the relaxation of peripheral vasculature and a reduction in systemic resistance.


Inhibition of Renal Na^+/ Cl^- Cotransporter ( NCC)

The second component modulates fluid and electrolyte homeostasis by acting as an inhibitor of the Na^+/ Cl^- Cotransporter ( NCC), located in the kidney's distal convoluted tubules. Blocking this transport mechanism prevents the reabsorption of sodium, chloride, and water from the renal filtrate back into the bloodstream. This molecular action increases the urinary excretion of electrolytes and water, resulting in a reduction of the circulating plasma volume.


Additive and Complementary Action

The two distinct mechanisms engage in a synergistic relationship, employing complementary pathways that modulate systemic pressure determinants. Losartan reduces vascular tone and antagonizes hormonal drives for volume expansion, while the diuretic component actively reduces existing volume via renal mechanisms. This combined mechanistic effect addresses both hormonal and volume-related factors, leading to a modulation of systemic vascular resistance and fluid balance.

Dosage and Administration Information

How Losartic Plus is Used

Losartic Plus is an oral, fixed-dose combination medication intended for long-term therapy in the management of high blood pressure. Its usage is highly structured by guidelines concerning dosage, frequency, and patient-specific conditions.

Administration and Dosage Principles

Category Instruction
Route of Administration The medicine is taken via the oral route as a film-coated tablet.
Standard Dosing Frequency The tablet is administered once daily.
Timing in Relation to Food May be taken with or without food.
Preparation Tablets should be swallowed whole with a glass of water.
Initial Use Context This combination is generally not used as initial therapy; it is reserved for adult patients whose blood pressure is not adequately controlled by either losartan or hydrochlorothiazide used alone.

The typical starting and usual maintenance dose for most adults is a tablet of 50 mg Losartan Potassium and 12.5 mg Hydrochlorothiazide once daily. The maximum recommended daily dose is a single tablet of the 100 mg/25 mg strength. Dosage adjustments, if required, should be made gradually, typically after approximately three to four weeks of therapy to allow the full antihypertensive effect to manifest.

Use in Specific Populations

Use of this fixed combination is not recommended in the pediatric population (under 18 years) due to limited clinical experience. Furthermore, the combination is contraindicated for use in patients with severe renal impairment (creatinine clearance le 30 mL/min) and severe hepatic impairment, as the initial low dose required for these conditions cannot be achieved with the fixed-dose tablet.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Losartic Plus

This overview provides a patient-friendly summary of the types of clinical studies that have been conducted for Losartic Plus (Losartan/Hydrochlorothiazide), according to scientific and regulatory bodies, detailing the scope of the research and the evidence gaps that have been noted.


Evidence for the Clinical Evaluation of High Blood Pressure

Clinical research exploring the medicine's role in high blood pressure uses Randomized Controlled Trials (RCTs). These studies examined specific metrics, including Systolic and Diastolic Blood Pressure, and reported data points related to changes in these measurements over defined intervals. Research explored the patterns of measurements when using the fixed combination versus its components taken separately. While this evidence contributes to understanding short-term blood pressure patterns, long-term data specific to the fixed-dose combination, when compared directly to its individual components, remain limited.

Evidence for Research into Stroke Outcomes and Key Limitations

The research supporting the study of stroke risk outcomes in certain patients is derived from large, long-term clinical trials. These studies focused specifically on adults diagnosed with both high blood pressure and Left Ventricular Hypertrophy (LVH), monitoring the occurrence of stroke and other major cardiovascular events over multiple years.

A significant limitation noted in the regulatory evidence is the statement that the finding related to stroke outcomes may not be applicable to Black patients in the LVH population. This represents a significant area of uncertainty where research is ongoing.

Evidence in Specific Patient Populations

The research has also explored populations beyond the general adult group. The combination medicine was evaluated in pediatric patients (children ages 6 and older) to examine measured changes in blood pressure. Studies also included adults with co-occurring conditions, such as metabolic syndrome. The general finding is that results apply only to the populations studied, and data for certain subgroups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Losartic Plus (FAQ)

Q: What happens if I accidentally take too much Losartic Plus?

A: Regulatory documents describe the most likely effects of taking too much of this medicine as experiencing hypotension, which means very low blood pressure. This can sometimes be accompanied by a very rapid heartbeat (tachycardia) or, in some cases, a very slow heartbeat (bradycardia). If these effects occur, official warnings indicate the need for immediate medical assistance.


Q: Can I stop taking Losartic Plus on my own if I feel better?

A: Official information describes this medicine as a long-term therapy for managing blood pressure. If treatment is discontinued, the blood pressure may increase. It is designed to provide sustained control over time.


Q: Does Losartic Plus need to be taken at a specific time each day?

A: The medicine is prescribed to be taken once daily. However, because Losartic Plus contains a diuretic component that increases urination, it is generally suggested to avoid taking it too close to bedtime. This timing is suggested to help manage the increased need to urinate, which could otherwise interfere with sleep.


Q: Does salt intake impact how Losartic Plus works?

A: Regulatory guidance acknowledges a connection between salt intake and the use of this medicine. Official documents state that patients who are on a low-salt or salt-free diet should consult their health professional regarding the use of this medicine. This guidance is in place because sodium intake and fluid balance are major factors in blood pressure management.


Q: Is Losartic Plus used for children?

A: The use of this fixed combination is not recommended in children and adolescents under 18 years of age. This is because the safety and effectiveness of the fixed combination in this pediatric population have not been established in studies.


Q: What is the primary focus of the research evidence for Losartic Plus?

A: The clinical research evidence primarily focuses on evaluating the medicine’s ability to change Systolic and Diastolic Blood Pressure measurements. It also includes studies on the reduction of stroke risk in specific patient groups with high blood pressure and Left Ventricular Hypertrophy (an enlargement of the heart muscle).


Q: Why do people commonly search for Losartic Plus and muscle weakness together?

A: Muscle weakness or cramps is a symptom that may be associated with a serious possible side effect of the medicine: high potassium levels (hyperkalemia) or low potassium levels (hypokalemia). These electrolyte imbalances are documented in the medicine’s safety profile, and high or low potassium can cause symptoms like muscle weakness or cramps.


Q: What are the different available dosage strengths for Losartic Plus?

A: According to official documentation, the fixed-dose combination is available in several tablet strengths of Losartan Potassium/Hydrochlorothiazide. These typically include the combinations of 50 mg/12.5 mg, 100 mg/12.5 mg, and 100 mg/25 mg.


Q: Is Losartic Plus available in a generic version?

A: Yes, regulatory records confirm that the Losartan Potassium and Hydrochlorothiazide combination is available as a generic medication in the U.S. and other regulated markets.


Q: What are the long-term data limitations noted for Losartic Plus?

A: Limitations noted in the official research evidence include the fact that long-term data specifically comparing the fixed combination directly to its individual components remain limited. Additionally, a noted limitation is that the finding regarding stroke outcomes may not be applicable to Black patients in the studied population.


Q: Is it common to take Losartic Plus for many years?

A: This medicine is indicated for the long-term therapy of high blood pressure. Since hypertension is a chronic condition that typically requires ongoing management, individuals often take this medicine for extended periods.


Q: Does Losartic Plus affect diabetes medications?

A: Regulatory documentation notes a specific contraindication for co-administration with the drug Aliskiren in patients who have diabetes. Additionally, regulatory documents warn that the diuretic component may be associated with an increase in blood sugar levels.


Q: Is Losartic Plus safe for people with known kidney problems?

A: The medicine is formally contraindicated for individuals with severe renal impairment (a specific level of poor kidney function). For people with existing kidney problems, official labeling notes a risk of worsening kidney function is possible.


Q: How was Losartic Plus first approved by the FDA (or similar regulatory body)?

A: The specific fixed-dose combination was first approved by the U.S. Food and Drug Administration (FDA) on April 28, 1995, under its original brand name application. This date marks the beginning of its regulated market availability.


Q: Is feeling tired a common side effect of Losartic Plus?

A: Regulatory data notes that asthenia (physical weakness or lack of energy) and fatigue were reported in studies. However, the incidence rate was similar to, or less than, that observed in patients taking a placebo (an inactive treatment). Therefore, based on the studies, it is not classified among the common adverse reactions caused by the medicine itself.


Q: Can I drink alcohol while taking Losartic Plus?

A: Official information indicates that the combined use of this medicine and alcohol may lead to additive effects that lower blood pressure. This combined effect increases the risk of symptoms like dizziness and lightheadedness, as documented in the product information.


Q: Can Losartic Plus pass into breast milk?

A: Official labeling states that it is unknown whether Losartan, one of the active ingredients, is excreted into human breast milk. Due to the potential risk to the infant, official information suggests that a decision must be made with a health professional regarding discontinuing nursing or discontinuing the medication.


Q: Is it normal to feel dizzy or lightheaded when starting Losartic Plus?

A: Dizziness is an officially classified Common side effect. Official labeling states that symptomatic hypotension (very low blood pressure) is more likely to occur at the beginning of treatment. This combination of factors indicates that the risk of dizziness and low blood pressure is elevated at the beginning of treatment.


Q: Can Losartic Plus cause a persistent dry cough?

A: While cough is occasionally reported in post-marketing and clinical experience, it is not classified in official documents as a Common adverse reaction of the combination medicine. This combination product (which contains an ARB) is often used as an alternative to drug classes that are more commonly associated with cough.


Q: Does Losartic Plus affect electrolyte levels, such as potassium?

A: Yes, the medicine is associated with a risk of electrolyte imbalance. The diuretic component primarily affects the risk of low potassium (hypokalemia), while the Losartan component can be associated with high potassium (hyperkalemia).


Q: What is the risk of taking potassium supplements with Losartic Plus?

A: Official interaction information states that the co-administration of potassium supplements and potassium-sparing diuretics is associated with an increased risk of hyperkalemia. Hyperkalemia is the medical term for high potassium levels in the blood, which may require monitoring.


Q: What does the research evidence indicate about the effectiveness of Losartic Plus?

A: The clinical evidence indicates that the combination is utilized for the sustained reduction of elevated blood pressure. The evidence indicates its use is also studied, in certain patients with Left Ventricular Hypertrophy (LVH), for the reduction of stroke risk.

How should Losartic Plus be stored and disposed of?

How to Store and Dispose of Losartic Plus

Losartan Potassium and Hydrochlorothiazide tablets must be stored at Controlled Room Temperature (CRT), which is between 20 C to 25 C (68 F to 77 F). The official label permits temporary temperature excursions between 15 C and 30 C.

The medication must be stored in the original container and kept tightly closed to ensure protection from excessive moisture.

Handling and Safety

As a mandatory safety precaution, the product must be kept out of reach of children.

Disposal

All unused or expired tablets must be disposed of according to local regulations for medicinal products. Specific guidance should be sought from a pharmacist or local environmental authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Losartic Plus found in:

A-Z Index: